Rituximab promotes long-term response for patients with immune destruction of ... Medical Xpress A new analysis concludes that rituximab, a drug commonly used to treat blood cancers, leads to treatment responses lasting at least five years in approximately one quarter of patients with low platelet counts and a risk of bleeding due to chronic ... |
